Gland Pharma

  • TickerGLAND
  • ISININE068V01023
  • ExchangeNational Stock Exchange of India
  • SectorPharmaceuticals & Biotechnology
  • CountryIndia
Tushar Manudhane
  • Tushar Manudhane
GLAND GLAND PHARMA (Health Care)

MOSL: GLAND PHARMA (Buy)-Complex products/newer markets to fortify gro...

GLAND PHARMA: Complex products/newer markets to fortify growth pace (GLAND IN, Mkt Cap USD8.4b, CMP INR3802, TP INR4460, 17% Upside, Buy)   Progressing well on scaling up manufacturing of the vaccine GLAND’s 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification. We raise our FY22E/FY23E EPS estimate by 8% each to factor in: a) in...

Tushar Manudhane
  • Tushar Manudhane
GLAND GLAND PHARMA (Health Care)

MOSL: GLAND PHARMA (Buy)-Complex products/newer markets to fortify gro...

GLAND PHARMA: Complex products/newer markets to fortify growth pace (GLAND IN, Mkt Cap USD8.4b, CMP INR3802, TP INR4460, 17% Upside, Buy)   Progressing well on scaling up manufacturing of the vaccine GLAND’s 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification. We raise our FY22E/FY23E EPS estimate by 8% each to factor in: a) in...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch